Prevention of vaccine-preventable diseases in children Infections and Infestations
Conditions
Interventions
Current interventions as of 14/10/2024:
The VIKAS study is a pragmatically oriented trial, designed to demonstrate the effectiveness of the interventions in real-world conditions. The interventions
Sponsors
Canadian Institutes of Health Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Communities: 1.1. Located in a catchment area of a health sub-centre assigned to the intervention group, 1.2. Designated as possible "missed community" (low immunisation area), and 1.3. Consent is received from community gatekeepers (local elected officials with territorial responsibility, such as the Pradhan (mayor)). 2. All adult (>18 years of age) participants in communities selected to receive the intervention will be eligible to participate 3. All frontline health workers in the intervention group with territorial responsibility for a community selected to receive the interventions will be included in the field interventions. 4. Participants in the baseline and end line cross-sectional household surveys are primary caregivers (usually mothers) and other adult (over age 18 years ) family members of immunisation-age (0 to 23 months) children. Participants are eligible for inclusion in the household surveys if they reside in a study cluster (rural health sub-centre) catchment area and in an immunisation microplan area designated as a possible low immunisation area, and provide written informed consent. We will exclude those not able to understand and speak Hindi or Urdu.
Exclusion criteria
Exclusion criteria: 1. Participation in Interventions: None. 2. Participation in data collection: We will exclude those not able to understand and speak Hindi or Urdu. Based on our experience, in this district, this criterion would result in exclusion of less than 1% of respondents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean number (count) of government-recommended first year of life vaccine doses received by children 12 to 23 months of age at study end line measured using patient records | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The (binary) proportion of vaccine received at study end line for children 12 to 23 months measured using patient records 2. The (binary) proportion of age-appropriate vaccine received at study end line, for children 0 to 11 months measured using patient records | — |
Countries
India
Contacts
Public ContactMira Johri
Outcome results
None listed